Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.49 |
| ▸ | PYCR1 | P32322 | 5/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29507220 | 1.00 | CSNK2A1 (0.49) | CSNK2A1PYCR1KCNH2ESR1ESR2 | |
| SCHEMBL15820796 | 0.84 | CSNK2A1 (0.49) | CSNK2A1PYCR1KCNH2MAPK1TSHR | |
| Tetrabuthylammonium SCHEMBL3968566 | 0.82 | CSNK2A1 (0.37) | CSNK2A1PYCR1LMNAHTT | |
| SCHEMBL26938806 | 0.81 | PYCR1 (0.45) | CSNK2A1PYCR1KCNH2ESR1ESR2 | |
| SCHEMBL2112768 | 0.79 | CSNK2A1 (0.51) | CSNK2A1PYCR1ESR1ESR2MAPK1 | |
| SCHEMBL1822997 | 0.79 | PYCR1 (0.44) | PYCR1TSHRL3MBTL1LMNAHTT | |
| SCHEMBL1581581 | 0.78 | CSNK2A1 (0.47) | CSNK2A1PYCR1KCNH2MAPK1TSHR | |
| SCHEMBL1096617 | 0.76 | CYP2A6 (0.49) | KCNH2MAPK1L3MBTL1LMNAHTT | |
| SCHEMBL17157309 | 0.76 | CSNK2A1 (0.49) | CSNK2A1KCNH2ESR1ESR2MAPK1 | |
| SCHEMBL5439280 | 0.76 | TRPV4 (0.34) | CSNK2A1ESR1ESR2HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361241-A1 | HPK1 INHIBITOR AND MEDICAL USE THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2025-11-27 | — | — | US | disclosed |
| US-12454534-B2 | Pyrrolo[2,3-b]pyrazines as HPK1 inhibitor and the use thereof | BEONE MEDICINES I GMBH (CH) | 2025-10-28 | — | — | US | disclosed |
| EP-4538274-A1 | HPK1 INHIBITOR AND MEDICAL USE THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2025-04-16 | — | — | EP | disclosed |
| US-11945782-B2 | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity | SRX CARDIO, LLC (US) | 2024-04-02 | — | — | US | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| WO-2023237085-A1 | HPK1 INHIBITOR AND MEDICAL USE THEREOF | 贝达药业股份有限公司 | 2023-12-14 | — | — | WO | disclosed |
| CN-116102550-A | HPK1 inhibitor and application thereof in medicine | 贝达药业股份有限公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-116082307-A | HPK1 inhibitor and application thereof in medicine | 贝达药业股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-115894480-A | HPK1 inhibitor and application thereof in medicine | 贝达药业股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| EP-1806332-A1 | BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS | Daiichi Sankyo Company, Limited (JP) | 2007-07-11 | — | — | EP | disclosed |
| EP-1781662-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | Pfizer, Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2007-01-18 | — | — | US | disclosed |
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2007-01-18 | — | — | US | disclosed |
| US-7151105-B2 | Inhibitors of Hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. (US) | 2006-12-19 | — | — | US | disclosed |
| US-20060122399-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2006-06-08 | — | — | US | disclosed |
| WO-2006018725-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | PFIZER INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| US-6465485-B1 | SUCH AS 7-CYANO-2-(2-(1-(4-(2-INDOLYL)CARBOXAMIDO)CYCLO-HEXYL)ETHYL)-1,2,3,4 -TETRAHYDROISOQUINOLINE; ANTIPSYCHOTIC AGENTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-10-15 | — | — | US | disclosed |
| EP-0983244-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2000-03-08 | — | — | EP | disclosed |
| WO-1998050364-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361241-A1 | HPK1 INHIBITOR AND MEDICAL USE THEREOF | STK11, STK35, STK10 | CSNK2A1 116/4885PYCR1 2532/4885KCNH2 4143/4885 |
| US-20060122399-A1 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | RNASE1, GTF3C4, POLRMT | CSNK2A1 784/4885PYCR1 1998/4885KCNH2 3594/4885 |
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | RNASE1, GTF3C4, POLRMT | CSNK2A1 784/4885PYCR1 1998/4885KCNH2 3594/4885 |
| US-12454534-B2 | Pyrrolo[2,3-b]pyrazines as HPK1 inhibitor and the use thereof | PDXK, STK25, STK35 | CSNK2A1 151/4885PYCR1 805/4885KCNH2 3339/4885 |
| US-11945782-B2 | Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate PCSK9 protein activity | LDLR, PCSK9, CETP | CSNK2A1 897/4885PYCR1 2259/4885KCNH2 4244/4885 |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | PDXK, DTYMK, HIPK1 | CSNK2A1 684/4885PYCR1 1663/4885KCNH2 3331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.